Moderna Reports Promising Response Rates For Skin Cancer Combo Therapy In Resistant Patients

Moderna announced positive Phase 1/2 clinical data for its investigational cancer therapy, mRNA-4359, in combination with pembrolizumab for checkpoint inhibitor-resistant/refractory melanoma, demonstrating an objective response rate (ORR) of 24% overall and 67% in PD-L1+ tumors, alongside a manageable safety profile. These promising results, to be presented at the 2025 ESMO Congress, indicate potential in a difficult-to-treat cancer population. Separately, the company also reported strong preliminary immunogenicity data for its 2025-2026 COVID-19 vaccine targeting the LP.8.1 variant, which collectively contributed to a 3.54% increase in MRNA stock.

Analysis

Moderna Inc. (MRNA) announced compelling Phase 1/2 clinical data for its investigational cancer therapy, mRNA-4359, in combination with pembrolizumab for checkpoint inhibitor-resistant/refractory (CPI-R/R) melanoma. The study demonstrated an overall objective response rate (ORR) of 24% and a disease control rate (DCR) of 60% across 29 evaluable patients. Notably, in patients with PD-L1+ tumors, the ORR surged to 67% (6 of 9 participants), indicating a strong signal in a specific patient subgroup.

The therapy, which targets immune escape pathways PD-L1 and IDO1, also exhibited a consistently manageable safety profile with no new immune-related adverse events, and the median duration of response (DOR) was not reached, suggesting durable responses. These results, slated for presentation at the 2025 ESMO Congress, are significant given the high unmet medical need in CPI-R/R melanoma.

Separately, Moderna also reported strong preliminary immunogenicity data for its 2025-2026 mNEXSPIKE COVID-19 vaccine, showing a greater than 16-fold increase in neutralizing antibodies against the LP.8.1 variant. The combined positive news flow from both its oncology and infectious disease pipelines contributed to a 3.54% increase in MRNA stock price, underscoring the potential breadth of Moderna's mRNA platform.

Key Decisions for Investors

• Investors should closely monitor the ongoing Phase 1/2 study and future trial readouts for mRNA-4359, as its promising early efficacy in CPI-R/R melanoma could significantly de-risk Moderna's oncology pipeline.
• Consider the implications of Moderna's diversified pipeline strength, with positive data from both oncology and infectious disease segments potentially reducing reliance on a single product and enhancing long-term growth prospects.
• Evaluate MRNA's current valuation against the backdrop of these positive clinical developments, assessing the potential for mRNA-4359 to become a meaningful revenue contributor in the high-value oncology market.